Benzinga··Vandana SinghTheravance Biopharma Crashes 27% After Phase 3 Study Failure
Theravance Biopharma shares plummet 27% after ampreloxetine fails Phase 3 trial; company cuts workforce 50% and reduces expenses 60%.
TBPHstrategic reviewbiotech
T
$TBPH
2 articles found0 positive
1 negative
1 neutral
Benzinga··Vandana Singh
The Motley Fool··Lawrence Rothman, CfaIrenic Capital Significantly Trims Papa John's Stake Amid Market Underperformance
Irenic Capital divests 70% of Papa John's stake due to underperformance, with stock down 30.7% over past year amid broader QSR sector challenges.
ITGRALKTPZZASHCTBPHsame-store sales declineunderperformance